Abstract
The efficacy and tolerability of long-term tenoxicam and piroxicam therapy were compared in patients with rheumatoid arthritis or degenerative osteoarthritis. Sixty consecutive patients were randomized to receive treatment with either oral tenoxicam or piroxicam; 30 patients had rheumatoid arthritis and 30 had osteoarthritis. Both drugs were given in a single daily dose of 20 mg for 12 months, and all patients enrolled in the study were evaluated for efficacy and tolerability on a monthly basis. The efficacy and tolerability of once-daily tenoxicam were found to be comparable to that of once-daily piroxicam therapy. Greater clinical improvement in the symptoms of rheumatoid arthritis and osteoarthritis was noted in the tenoxicam-treated patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
